August 20, 2024 | BALTIMORE – Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are embarking on a groundbreaking collaboration set to redefine the landscape of single-cell multi-omics. By merging their cutting-edge technologies, this dynamic alliance is poised to revolutionize disease research and precision medicine, pushing the boundaries of what’s possible in healthcare innovation.
This collaboration unites M20 Genomics’ innovative single-cell and spatial transcriptomics platforms with Complete Omics’ leading proteomics and metabolomics technologies. By combining these powerful tools, the partnership will enable comprehensive multi-omics analysis at the single-cell level, providing researchers with unprecedented insights into cellular heterogeneity, tissue architecture, and disease mechanisms. This integration is expected to enhance the precision and application of multi-omics technologies in disease research and personalized medicine.
Establishment of Joint Laboratory
A key aspect of this collaboration is setting up a joint laboratory in Baltimore, Maryland, close to Johns Hopkins University. This lab will serve as a hub for developing and optimizing integrated single-cell multi-omics assays, merging M20 Genomics’ single-cell and spatial transcriptomics expertise with Complete Omics’ proteomics and metabolomics technologies. Both companies aim to create powerful tools for multi-omics research, enabling detailed mapping of gene, protein, and metabolite expression at the single-cell level. The joint lab will facilitate the development of innovative multi-omics technologies, pushing the boundaries of biomedical research.
Driving Collaborative Research
This partnership will also foster collaborative research with leading academic institutions, including Johns Hopkins University. The collaboration will focus on high-impact areas such as antimicrobial resistance, gut microbiome research, cancer, and metabolic disorders. By leveraging the complementary strengths of both companies, the partnership will advance personalized medicine and drive innovations in disease understanding and clinical applications.
Expanding Multi-Omics Insights
Through this collaboration, M20 Genomics and Complete Omics will significantly enhance their combined capacity to offer researchers deeper insights into cellular processes and disease mechanisms. The integration of single-cell and spatial transcriptomics with proteomics and metabolomics will pave the way for new avenues in precision medicine, enabling a deeper understanding of disease mechanisms at a molecular level. This joint effort aims to accelerate discoveries and improve clinical outcomes by offering comprehensive multi-omics profiling and more precise disease analysis.
This strategic collaboration is poised to drive innovations in single-cell and spatial multi-omics, enabling new breakthroughs in research and clinical applications.
About M20 Genomics
M20 Genomics is a rapidly growing life science technology company dedicated to pushing the boundaries of single-cell technology. The company’s mission is to empower customers to break through technological barriers by providing cutting-edge single-cell and spatial technology solutions. M20 Genomics is committed to deliver novel and innovative solutions to meet the needs of customers, and help drive advancement in research discovery, and applications towards disease diagnosis and treatment.
With its proprietary “M20 Seq” technology, M20 Genomics has pioneered the world’s first high-throughput full-length single-cell technology sequencing using random primers, along with the VITA product line for single-cell transcriptome sequencing. The “M20 Spatial” technology, utilizing random primers and paired with the NATA spatial transcriptome product line, provides the first spatial full-transcriptome solution across various sample types.
For more information, please visit M20 Genomics.
About Complete Omics
Complete Omics, founded in 2019 at Johns Hopkins University, is at the forefront of clinical proteomics. The company’s founding team includes experts from Johns Hopkins University School of Medicine and AstraZeneca, with a cumulative contribution of over 600 peer-reviewed publications, including in prestigious journals like Cell, Nature, Science, and the New England Journal of Medicine.
With nearly 20 years of multi-omics expertise and over 20 proprietary patents, Complete Omics has developed state-of-the-art platforms for clinical proteomics and molecular diagnostics. The company collaborates with over 100 global research institutions and pharmaceutical companies, having processed more than one million samples and contributed to numerous high-impact publications. Complete Omics is dedicated to transforming scientific innovation into clinical applications, offering comprehensive solutions that drive advancements in companion diagnostics and personalized medicine.
